LLY Jun 2024 420.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:36PM EDT. Market open.
| Previous close | 362.14 |
| Open | 362.14 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 420.00 |
| Expiry date | 2024-06-21 |
| Day's range | 362.14 - 362.14 |
| Contract range | N/A |
| Volume | |
| Open interest | 92 |
ReutersEli Lilly's diabetes drug tirzepatide gets approval in China
Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market. Novo Nordisk's popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8 billion Danish Krone ($698 million) last year. Eli Lilly did not say when sales would begin in China or how many doses would be supplied.
Investor's Business DailyMagnificent Seven? Just Two Members Clear This Bar
Ultimately, earnings drive share prices. Only two Magnificent Seven stocks, and a third megacap, meet this triple-25% growth standard.
ZacksThe Zacks Analyst Blog Highlights Microsoft, Eli Lilly, Costco and Koss
Microsoft, Eli Lilly, Costco and Koss are included in this Analyst Blog.
© 2024 Yahoo. All rights reserved.